Celixir
Cardiff
About Celixir
Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchers to discover breakthrough medicines that aim to change the standard of medical care for patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.6M
- Last round: Series Unknown (Mar 2018)
- Website: celixir.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/celixir-81710 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.